A new approach to delineating clinical target volume for radiotherapy of glioblastoma: A phase II trial.

Front Oncol · 2022 · PMC9626993 · PMID 36338715

Europe PMC DOI

hedged sentence

0.2570

closest p · 5.1× alpha

0.2570

boldest claim

The sentences

showed a trendp = 0.257not close (p > 0.1)

Our regimen showed a trend of lower rates of marginal recurrence, and the brain volume of high-dose radiation fields in our regimen was similar to that of EORTC (p = 0.257).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.